drugset / Trial / NCT05452304

AZD7798 Safety, Tolerability, and Pharmacokinetics After a Single Ascending and Repeat Dose Administrations to Healthy Subjects, and Patients With Crohn's Disease

NCT05452304 ↗

Phase 1 Completed 112 enrolled AstraZeneca Parexel · collab
RandomizedSequentialQuadruple-blindTreatment

Summary

This study will assess the safety, tolerability, immunogenicity, and pharmacokinetics (PK), and explore the pharmacodynamics (PD) following single ascending dose administration and repeat dose administration in healthy subjects and patients with Crohn's disease.

Timeline

Start
2022-07-12
Primary completion
2024-11-14
Completion
2024-11-27

Drugs

EvaluationDrugModalityDoseRoute
Subject AZD7798 Unknown — —

Indications